ATE468328T1 - Multimere von pyrimidinonderivaten und deren verwendung als inhibitoren der humanen neutrophilelastase - Google Patents
Multimere von pyrimidinonderivaten und deren verwendung als inhibitoren der humanen neutrophilelastaseInfo
- Publication number
- ATE468328T1 ATE468328T1 AT06709612T AT06709612T ATE468328T1 AT E468328 T1 ATE468328 T1 AT E468328T1 AT 06709612 T AT06709612 T AT 06709612T AT 06709612 T AT06709612 T AT 06709612T AT E468328 T1 ATE468328 T1 AT E468328T1
- Authority
- AT
- Austria
- Prior art keywords
- elastasis
- multimers
- inhibitors
- human neutrophil
- pyrimidinone derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0502258.7A GB0502258D0 (en) | 2005-02-03 | 2005-02-03 | Compounds and their use |
| PCT/GB2006/000361 WO2006082412A2 (en) | 2005-02-03 | 2006-02-03 | Multimers of pyrimidinone derivatives and their use as human neutrophil elastase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE468328T1 true ATE468328T1 (de) | 2010-06-15 |
Family
ID=34307936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06709612T ATE468328T1 (de) | 2005-02-03 | 2006-02-03 | Multimere von pyrimidinonderivaten und deren verwendung als inhibitoren der humanen neutrophilelastase |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090111795A1 (de) |
| EP (1) | EP1856059B1 (de) |
| JP (1) | JP2008528670A (de) |
| CN (1) | CN101151252A (de) |
| AT (1) | ATE468328T1 (de) |
| AU (1) | AU2006210730B2 (de) |
| CA (1) | CA2595801A1 (de) |
| DE (1) | DE602006014367D1 (de) |
| GB (1) | GB0502258D0 (de) |
| WO (1) | WO2006082412A2 (de) |
| ZA (1) | ZA200707009B (de) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0302486D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| GB0520743D0 (en) * | 2005-10-12 | 2005-11-23 | Argenta Discovery Ltd | Compounds and their use |
| US8198288B2 (en) | 2006-05-04 | 2012-06-12 | Pulmagen Therapeutics (Inflammation) Limited | Tetrahydropyrrolopyrimidinediones and their use in therapy |
| WO2009013444A1 (en) * | 2007-07-25 | 2009-01-29 | Argenta Discovery Limited | Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors |
| PT2024367E (pt) | 2006-05-04 | 2010-12-03 | Pulmagen Therapeutics Inflammation Ltd | Tetra-hidropirrolopirimidinadionas e a sua utilização a título de inibidores da elastase de neutrófilos humana |
| TW200808763A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
| TW200808771A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
| EP2064184A1 (de) * | 2006-09-04 | 2009-06-03 | AstraZeneca AB | Als inhibitoren der neutrophilen-elastase geeignete multimere heterocyclische verbindung |
| PT2164501E (pt) * | 2007-05-31 | 2016-06-02 | Paradigm Biopharmaceuticals Ltd | Xilanos sulfatados para tratamento ou profilaxia de doenças respiratórias |
| US8466284B2 (en) | 2007-11-06 | 2013-06-18 | Astra Zeneca Ab | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
| WO2009060158A1 (en) * | 2007-11-07 | 2009-05-14 | Argenta Discovery Limited | 4- (4-cyanophenyl) -1- (3-trifluoromethylphenyl) -3,4, 6, 7-tetrahydro-1h-pyrrolo [3, 4- d] pyrimidine-2, 5-dione derivatives and their use as human neutrophil elastase inhibitors |
| SI2229358T1 (sl) | 2007-12-14 | 2011-10-28 | Pulmagen Therapeutics Asthma Ltd | Indoli in njihova terapevtska uporaba |
| NZ586263A (en) | 2007-12-20 | 2012-06-29 | Bayer Schering Pharma Ag | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof |
| DE102007061766A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung |
| DE102008052013A1 (de) | 2008-10-17 | 2010-04-22 | Bayer Schering Pharma Aktiengesellschaft | 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung |
| DE102008022521A1 (de) | 2008-05-07 | 2009-11-12 | Bayer Schering Pharma Aktiengesellschaft | 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung |
| BRPI1005684A2 (pt) * | 2009-01-30 | 2018-06-12 | Chiesi Farm Spa | pirrolopirimidinedione dimérico e seu uso em terapias de doenças respiratórias |
| GB0902648D0 (en) | 2009-02-17 | 2009-04-01 | Argenta Discovery Ltd | Pharmaceutical compounds and compositions |
| BRPI1005327A2 (pt) | 2009-02-17 | 2019-09-24 | Chiesi Farm Spa | derivados de triazolopiridina como inibidores de p38 map quinase |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| DE102009016553A1 (de) | 2009-04-06 | 2010-10-07 | Bayer Schering Pharma Aktiengesellschaft | Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung |
| EP2483244A1 (de) | 2009-10-02 | 2012-08-08 | AstraZeneca AB | 2-pyridonverbindungen als neutrophilenelastase-hemmer |
| GB201004178D0 (en) * | 2010-03-12 | 2010-04-28 | Pulmagen Therapeutics Inflamma | Enzyme inhibitors |
| GB201009731D0 (en) | 2010-06-10 | 2010-07-21 | Pulmagen Therapeutics Inflamma | Kinase inhibitors |
| DE102010030187A1 (de) | 2010-06-16 | 2011-12-22 | Bayer Schering Pharma Aktiengesellschaft | 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung |
| EP2766366B1 (de) | 2011-09-14 | 2016-11-09 | Chiesi Farmaceutici S.p.A. | Tetrahydrotriazolopyrimidine derivate als inhibitoren der humanen neutrophilen elastase |
| WO2013083206A1 (en) | 2011-12-09 | 2013-06-13 | Chiesi Farmaceutici S.P.A. | Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract |
| EP2788349B1 (de) | 2011-12-09 | 2016-10-26 | Chiesi Farmaceutici S.p.A. | Kinase-inhibitoren |
| JP6145849B2 (ja) | 2011-12-09 | 2017-06-14 | チエシ ファルマスーティシ エス．ピー．エー． | キナーゼ阻害剤 |
| US9644076B2 (en) | 2012-09-25 | 2017-05-09 | Max-Planck-Gesellschaft zur Foerderung der Wissenschafen e. V. | Cross-linkers for hydrogels, hydrogels including these cross-linkers and applications thereof |
| US20140221335A1 (en) | 2013-02-06 | 2014-08-07 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9115093B2 (en) | 2013-03-04 | 2015-08-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| KR20160018567A (ko) | 2013-06-06 | 2016-02-17 | 키에시 파르마슈티시 엣스. 피. 에이. | 키나아제 억제제 |
| USRE47493E1 (en) | 2014-02-20 | 2019-07-09 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9475779B2 (en) | 2014-07-31 | 2016-10-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9290457B2 (en) | 2014-07-31 | 2016-03-22 | Boehringer Ingelheim International Gmbh | Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9458113B2 (en) | 2014-07-31 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9657015B2 (en) | 2014-07-31 | 2017-05-23 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US9440930B2 (en) | 2014-07-31 | 2016-09-13 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| WO2016146607A1 (de) | 2015-03-18 | 2016-09-22 | Bayer Pharma Aktiengesellschaft | Verfahren zur herstellung von (4s)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluormethyl)phenyl]-1,2,3,4-tetrahydro pyrimidin-5-carbonitril |
| TW201720828A (zh) | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| AR107163A1 (es) | 2015-12-23 | 2018-03-28 | Chiesi Farm Spa | Inhibidores de quinasa |
| AR107164A1 (es) | 2015-12-23 | 2018-03-28 | Chiesi Farm Spa | INHIBIDORES DE QUINASA p38 |
| AR107165A1 (es) | 2015-12-23 | 2018-03-28 | Chiesi Farm Spa | Inhibidores de quinasa |
| EP3452464B1 (de) | 2016-05-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Pyrazol derivate, zusammensetzungen und deren therapeutische anwendung |
| CN109890817B (zh) | 2016-09-06 | 2022-06-17 | 豪夫迈·罗氏有限公司 | 8-(氮杂环丁烷-1-基)-[1,2,4]三唑并[1,5-a]吡啶基化合物、其组合物和应用方法 |
| JP6900491B2 (ja) | 2016-12-29 | 2021-07-07 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ピラゾロピリミジン化合物及びその使用方法 |
| JP2020510061A (ja) | 2017-03-14 | 2020-04-02 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ピラゾロクロロフェニル化合物、組成物及びその使用方法 |
| WO2018215389A1 (en) | 2017-05-22 | 2018-11-29 | F. Hoffmann-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
| US20180334465A1 (en) | 2017-05-22 | 2018-11-22 | Genentech, Inc. | Therapeutic compounds and compositions, and methods of use thereof |
| US10364245B2 (en) | 2017-06-07 | 2019-07-30 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
| EP3740488A1 (de) | 2018-01-15 | 2020-11-25 | F. Hoffmann-La Roche AG | Pyrazolopyrimidinverbindungen als jak-hemmer |
| TW202115069A (zh) | 2019-06-18 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | Ｊａｋ激酶之經四唑取代之吡唑并嘧啶抑制劑及其用途 |
| JP2022537354A (ja) | 2019-06-18 | 2022-08-25 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｊａｋキナーゼのピラゾロピリミジンアリールエーテル阻害剤及びその使用 |
| AU2020297415A1 (en) | 2019-06-18 | 2022-01-06 | F. Hoffmann-La Roche Ag | Pyrazolopyrimidine sulfone inhibitors of JAK kinases and uses thereof |
| CN114650819A (zh) | 2019-09-17 | 2022-06-21 | 美莱奥生物制药第四有限公司 | 用于治疗移植物排斥、闭塞性细支气管炎综合征和移植物抗宿主病的阿维来司他 |
| EP4252850A3 (de) | 2020-04-16 | 2023-11-15 | Mereo Biopharma 4 Limited | Methoden beinhaltend neutrophile elastase inhibitor alvelestat zur behandlung von atemwegserkrankung aufgrund von alpha-1 antitrypsin mangel |
| WO2023067103A1 (en) | 2021-10-20 | 2023-04-27 | Mereo Biopharma 4 Limited | Neutrophil elastase inhibitors for use in the treatment of fibrosis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2498052C (en) * | 2002-09-10 | 2011-05-17 | Bayer Healthcare Ag | Heterocyclic derivatives |
| MXPA05002644A (es) * | 2002-09-10 | 2005-09-20 | Bayer Healthcare Ag | Derivados de pirimidinona como agentes terapeuticos contra procesos de remodelacion, isquemicos e inflamatorios agudos y cronicos. |
| EP1730121B1 (de) * | 2004-02-26 | 2013-08-07 | Bayer Intellectual Property GmbH | 1,4-diaryldihydropyrimidin-2-one und deren verwendung als inhibitoren der humanen neutrophilen elastase |
| CA2557271C (en) * | 2004-02-26 | 2012-08-21 | Bayer Healthcare Ag | 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors |
-
2005
- 2005-02-03 GB GBGB0502258.7A patent/GB0502258D0/en not_active Ceased
-
2006
- 2006-02-03 WO PCT/GB2006/000361 patent/WO2006082412A2/en active Application Filing
- 2006-02-03 EP EP06709612A patent/EP1856059B1/de not_active Revoked
- 2006-02-03 JP JP2007553695A patent/JP2008528670A/ja not_active Withdrawn
- 2006-02-03 CN CNA2006800098569A patent/CN101151252A/zh active Pending
- 2006-02-03 US US11/814,615 patent/US20090111795A1/en not_active Abandoned
- 2006-02-03 CA CA002595801A patent/CA2595801A1/en not_active Abandoned
- 2006-02-03 ZA ZA200707009A patent/ZA200707009B/xx unknown
- 2006-02-03 AT AT06709612T patent/ATE468328T1/de not_active IP Right Cessation
- 2006-02-03 DE DE602006014367T patent/DE602006014367D1/de active Active
- 2006-02-03 AU AU2006210730A patent/AU2006210730B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006210730A1 (en) | 2006-08-10 |
| AU2006210730B2 (en) | 2009-12-03 |
| CA2595801A1 (en) | 2006-08-10 |
| WO2006082412A2 (en) | 2006-08-10 |
| CN101151252A (zh) | 2008-03-26 |
| JP2008528670A (ja) | 2008-07-31 |
| GB0502258D0 (en) | 2005-03-09 |
| ZA200707009B (en) | 2008-11-26 |
| DE602006014367D1 (de) | 2010-07-01 |
| US20090111795A1 (en) | 2009-04-30 |
| EP1856059B1 (de) | 2010-05-19 |
| EP1856059A2 (de) | 2007-11-21 |
| WO2006082412A3 (en) | 2006-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE468328T1 (de) | Multimere von pyrimidinonderivaten und deren verwendung als inhibitoren der humanen neutrophilelastase | |
| ATE537830T1 (de) | Nicotinamid derivate und ihre verwendung als therapeutika | |
| EA200802213A1 (ru) | Способы лечения заболеваний крови | |
| ATE413392T1 (de) | Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren | |
| NO20080408L (no) | Azaindazolforbindelser og anvendelse derav | |
| NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
| ATE406351T1 (de) | Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren | |
| CY1110962T1 (el) | Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων | |
| BRPI0515505A (pt) | derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase | |
| BRPI0418251A (pt) | fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais | |
| TW200634012A (en) | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | |
| BRPI0515482A (pt) | derivados heterocìclicos e seus usos como agentes terapêuticos | |
| ATE480543T1 (de) | Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase | |
| ECSP088869A (es) | Derivados de 2-pirazinona para el tratamiento de enfermedades o condiciones en donde resulta beneficiosa la inhibición de la actividad de la elastasa neutrofílica | |
| MX2012003644A (es) | Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila. | |
| CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
| DE602005017626D1 (de) | Antivirale verwendung von borinsäurekomplexen | |
| DE602005023124D1 (de) | Spirobenzodioxole und deren verwendung als cb1-antagonisten | |
| ATE446089T1 (de) | 2-benzoyl-imidazopyridin-derivate, herstellungsverfahren und ihre verwendung für therapeutika | |
| ATE396970T1 (de) | 2-(1h-indolylsulfanyl)-benzylaminderivate als ssri | |
| DE602005009500D1 (de) | Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors | |
| ATE508125T1 (de) | Triazoloanilinopyrimidinderivate zur verwendung als antivirale mittel | |
| DE602005001918D1 (de) | S-tenatoprazolnatrium-monohydrat-salz und dessen verwendung in form eines protonenpumpenhemmers | |
| DE602007010038D1 (de) | Pyrimidylderivate als proteinkinaseinhibitoren | |
| NO20081195L (no) | Imidazopyridinderivater som kannabinoidreceptorligander |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |